Penn Medicine Provider
Medical Oncology
Aditi P. Singh, MD
5.0
(267)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Lady Hardinge Medical College
  • Residency: University of Alabama at Birmingham (UAB Hospital)
  • Residency: Tufts - New England Medical Center
  • Fellowship: Montefiore Medical Center

What my patients think about me

Average Rating
5.0

268 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
professional and patient doctor.
May 2025
5.0
5.0
dr. singh is wonderful, she takes time to really listen to me and answers all my questions completely. she is very knowledgeable and receptive to my needs.
May 2025
5.0
5.0
first visit with doctor. i will have to see how follow through is
April 2025
5.0
5.0
dr. singh is very thorough and compassionate.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Singh is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Aditi P Singh, Abigail T Berman, Melina E Marmarelis, Andrew R Haas, Steven J Feigenberg, Jennifer Braun, Christine A Ciunci, Joshua M Bauml, Roger B Cohen, John C Kucharczuk, Lawrence N Shulman, Corey J Langer, Charu Aggarwal Management of Lung Cancer During the COVID-19 Pandemic , JCO Oncol Pract, 16(9): 2020,579-586


Charu Aggarwal, Jeffrey C. Thompson, Austin L. Chien, Katie J. Quinn, Wei-Ting Hwang, Taylor A. Black, Stephanie S. Yee, Theresa E. Christensen, Michael J. LaRiviere, Benjamin A. Silva, Kimberly C. Banks, Rebecca J. Nagy, Elena Helman, Abigail T. Berman, Christine A. Ciunci, Aditi P. Singh, Jeffrey S. Wasser, Joshua M. Bauml, Corey J. Langer, Roger B. Cohen and Erica L. Carpenter Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer , Clin Cancer Res , 26(10): 2020,2354-2361


Aditi P. Singh, Elaine Shum, Lakshmi Rajdev, Haiying Cheng, Sanjay Goel, Roman Perez-Soler, Balazs Halmos Impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice , Cancers, 12(5): 2020,1156


Qinfang Deng, Qiyu Fang, Hui Sun Aditi P. Singh, Mariam Alexander, Shenduo Li, Haiying Cheng, Songwen Zhou. Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis , Cancer Med, 9(6): 2020,2085-2095


Attarian S, Guo X, Ko B, Singh AP, Castellucci E, Gucalp R, Haigentz M, Cheng H, Halmos B. Lung cancer in patients with HIV - Unique features impacting lung cancer screening and management , World Lung Cancer Conference - Virtual Meeting: 2019


Singh AP, Alexander M, Goradia N, Cheng H Practical Advice for Treating Leptomeningeal Disease in Non–Small Cell Lung Cancer , The Journal of Targeted Therapies in Cancer, 26(9): 2018


Singh AP, Cheng H, Guo X, Levy B, Halmos B. Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician , Journal of Clinical Oncology/Precision Oncology : 2017


Singh AP, Li S, Cheng H. Circulating DNA in EGFR-mutated lung cancer. , Ann Transl Med, 5(18): 2017,379


Hardin C, Shum E, Singh AP, Perez-Soler R, Cheng H. Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. , Expert Opin Pharmacother, 18(7): 2017,701-716


Puri Singh A, Haywood C Jr, Beach MC, Guidera M, Lanzkron S, Valenzuela-Araujo D, Rothman RE, Dugas AF. Improving Emergency Providers' Attitudes Toward Sickle Cell Patients in Pain. , J Pain Symptom Manage, 51(3): 2016,628-32